glp 1 parkinson's disease and neuroprotection PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's models Incretin Hormones GLP-1 and GIP

Before recommending peptide therapy, our providers may evaluate: Your health goals Current symptoms Injury or recovery concerns Medical history Medication and supplement use Sleep, stress, and lifestyle factors Mental health history Hormonal or metabolic concerns Lab testing when appropriate Safety risks and contraindications If peptide therapy is appropriate, your provider will explain the recommended approach, possible benefits, limitations, risks, and follow-up plan

EU research contract GAP-2014-655232

In an earlier 54-week study, 9 of 23 patients who received liraglutide had resolution of definite non-alcoholic steatohepatitis compared to 2 of 22 patients in the placebo group (NCT01237119)

A consultation with our medical team is required to determine if this therapy is appropriate for you

W.KelleyK